Los 10 principales competidores de scitechnol.com

nerdyelectronics.com

We will...a simple IoT Project, where...read the temperature sensor data and send it to cloud for storage. We...temperature in AWS DynamoDB.

ijetrm.com

ijetrm is international journal which double-blind peer reviews published research papers for engineering & management journal with fast publication and low fee.

scholarscentral.org

submission and review tracking system was founded with a mission to provide free access to scientific literature for quick dissemination of scientific updates and to provide a source of reference and retrieval free of cost.

ukscip.com

uk scientific publishing limited

vjst.vn

Là cơ quan báo chí thực hiện chức năng thông tin, lý luận chuyên ngành, phục vụ công tác quản lý nhà nước của Bộ Khoa học và Công nghệ, công bố khoa học trong các lĩnh vực

lupus.bmj.com

Objective To evaluate the feasibility, usability and acceptability of implementing a treat-to-target (T2T) strategy supported by a Clinical Decision Support System (CDSS), in routine SLE outpatient care.Methods A 24-week, non-randomised, multicentre, clustered pilot study was conducted across four rheumatology outpatient centres. Adult patients with SLE were allocated by centre to either a T2T strategy supported by a CDSS (T2T-CDSS) or a routine outpatient care (ROC) group. The CDSS provided evidence-based treatment recommendations based on disease activity measures. Feasibility outcomes included recruitment and retention rates. Usability was assessed with the System Usability Scale (SUS), completed by physicians in the T2T-CDSS group. Acceptability was evaluated using the Treatment Satisfaction Questionnaire (TSQ) and qualitative feedback. Exploratory outcomes included disease activity, remission rates and treatment modifications.Results Of 91 screened patients, 38 were enrolled (recruitment rate 42%) and 35 completed the study (retention rate 92%). The SUS score for the CDSS was 73.8, indicating good usability. Global satisfaction scores on the TSQ were stable over time and comparable between groups. Remission was achieved at least once by 61% (11/18) of patients in the T2T-CDSS group and 59% (10/17) in the ROC group. Both treatment intensifications and de-escalations occurred more frequently in the T2T-CDSS group compared with ROC (83% vs 47%). Treatment intensifications were observed in 61% of patients in the T2T-CDSS group vs 29% in the ROC group. Treatment de-escalation, represented by glucocorticoid tapering, occurred in 39% of T2T-CDSS patients compared with 18% in ROC. No statistically significant differences were observed between groups in disease activity outcomes or remission rates.Conclusions Implementation of a T2T strategy supported by a CDSS in SLE outpatient care was feasible, usable and acceptable to patients and physicians. Although qualitative fe